Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma

Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Oxcarbazepine Efficacy in Asthma Therapy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00142025

Enrollment

Registered

2005-09-02

Start date

2001-09-30

Completion date

2002-03-31

Last updated

2009-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Asthma

Keywords

Bronchial asthma, Oxcarbazepine, Antiepileptic drug, Efficacy

Brief summary

The purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma.

Detailed description

Effective therapy of asthma still remains quite serious problem. According GINA definition, asthma is an inflammatory disorder. Consequently, modern pharmacotherapy of asthma provides wide use of anti-inflammatory drugs. But asthma also is a paroxysmal disorder: many specialists and even some guidelines underline paroxysmal clinical picture of asthma. Besides this, according to some authors, neurogenic inflammation may play important role in asthma mechanism. But some other neurogenic inflammatory paroxysmal disorders exist, and they are migraine and trigeminal neuralgia. Some antiepileptic drugs, like carbamazepine and valproate, are very effective in therapy of migraine and trigeminal neuralgia - more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, like migraine and trigeminal neuralgia, it is possible that some antiepileptic drugs also are very effective in asthma therapy. We performed a double-blind, placebo-controlled 3-month trial for evaluation of oxcarbazepine efficacy in therapy of bronchial asthma. Oxcarbazepine is antiepileptic drug of new generation, produced by Novartis, and it is more effective and safe derivative of well-known antiepileptic drug carbamazepine. Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.

Interventions

DRUGOxcarbazepine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

17 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Bronchial asthma has been known at least for 1 year * Absence of long-term remissions of asthma (lasting more than 1 month) * Poorly controlled asthma, due to various reasons * Non-smokers

Exclusion criteria

* Presence of concomitant severe diseases * Allergy or adverse reactions to carbamazepine or oxcarbazepine * Abnormal baseline haematology, blood chemistry or urinalysis * Current use of long-acting beta-agonists * Age younger than 16 years old * Long-term history of smoking * Pregnancy or lactating

Design outcomes

Primary

Measure	Time frame
At 3 months of treatment: Change from baseline of the FEV1 and PEFR (also %predicted); Number of patients without asthma symptoms	—

Secondary

Measure	Time frame
At 3 months of treatment: FEV1 before and after salbutamol inhalation; Difference in PEF pm-am (in %); The daily (daytime and night-time) symptoms scores; % of symptom free days during the treatment period; Use of other antiasthmatic medication	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026